Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210284
Abstract: Aim To analyze the efficacy and safety of Ixazomib, pomalidomide and dexamethasone (IxaPD) regimen in patients with refractory and relapsed multiple myeloma（RRMM）. Methods Clinical data of RRMM patients were prospectively collected from 5 centers in… read more here.
Keywords: multiple myeloma; treatment; refractory; ixazomib pomalidomide ... See more keywords